← All trials
NCT05504226
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Nov 30, 2024
- Completion date
- May 31, 2025
- First posted
- Aug 17, 2022
- Last posted
- Aug 17, 2022
- Enrollment
- 208
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Handok Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.